Browsing by Author "Sendra, Luis"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation
    (2015) Sánchez Lazaro, Ignacio; Herrero, Maria Jose; Jordan-De Luna, Consuelo; Boso, Virginia; Almenar, Luis; Rojas Orellana, Luis; Martínez Dolz, Luis; Megías Vericat, Juan E.; Sendra, Luis; Miguel, Antonio; Poveda, José L.; Aliño, Salvador F.
  • No Thumbnail Available
    Item
    Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up
    (2022) Sendra, Luis; Olivera, Gladys G.; Lopez-Andujar, Rafael; Serrano, Cristina; Rojas, Luis E.; Maria Montalva, Eva; Jose Herrero, Maria; Alino, Salvador F.
    Some gene polymorphisms have been previously associated individually with tacrolimus efficacy and toxicity, but no long-term study to determine the role of pharmacogene variants in the clinical evolution of liver-transplanted patients has been addressed so far. In the present work, we analyzed the relation between highly-evidenced genetic polymorphisms located in relevant pharmacogenes and the risk of suffering premature death and other comorbidities such as cancer, diabetes mellitus, arterial hypertension, graft rejection, infections and nephrotoxicities in a cohort of 87 patients (8 were excluded due to early loss of follow-up) transplanted at Hospital La Fe in Valencia (Spain) during a 12-year follow-up. Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes. In this sense, our results show an association between MTHFR gene variants in donor rs1801133 (HR: 7.90; p-value: 0.032) and recipient rs1801131 (HR: 7.34; p-value: 0.036) and the group of patients who died during the follow-up period, supporting the interest of confirming these results with larger patient cohorts. In addition, donor polymorphisms in UGT1A9 metabolizer gene rs6714486 (OR: 0.13; p-value: 0.032) were associated with a lower risk of suffering from de novo cancer. Genetic variants in CYP2B6 metabolizer gene rs2279343 demonstrated an association with a risk of infection. Other variants in different locations of SLCO1A2, ABCC2 and ABCB1 transporter genes were associated with a lower risk of suffering from type 2 diabetes mellitus, chronic and acute nephrotoxicities and arterial hypertension. Results suggest that pharmacogenetics-derived information may be an important support for personalized drug prescription, clinical follow-up and the evolution of liver-transplanted patients.